Manufacturing Daily Summary
Manufacturing Daily Summary: What Happened on October 13, 2026
Bio-Techne opens Bristol GMP facility for cell therapy materials
The 10,000-square-foot site is producing small molecules for cell therapy developers.
Today in brief
Bio-Techne has begun making GMP-grade small molecules for cell therapy developers at a new Bristol site.1
Manufacturing
Bio-Techne opened a 10,000-square-foot facility in Bristol to manufacture GMP-grade small molecules for cell therapy developers.1 The site has five multifunctional ISO-8 cleanrooms and two ISO-7 cleanrooms, and is already producing materials for customers.1
The facility extends Bio-Techne’s US GMP manufacturing capabilities and adds small-molecule production to its portfolio.1
Also published
- Waiting for Perfect Data Is the Biggest Mistake in Pharma Supply Chains Pharmaceutical Executive
- The Bottlenecks That Slow Manufacturer Response to Increased Demand for Production Pharmaceutical Executive
- What Best-In-Class Supply Chain Data Infrastructure Looks Like Today: LogiPharma 2026 Pharmaceutical Executive
- The Manufacturing Issues That Continue to Contribute to Drug Shortages Pharmaceutical Executive